Table 4 Evaluation of microRNA performance in predicting 1 year risk of mortality.

From: microRNA associated with hepatocyte injury and systemic inflammation may predict adverse outcomes in cirrhotic patients

microRNA

N

SHR (95% CI)

(A)

 miR-103a

154

1.00 (0.82–1.21)

 miR-122

154

1.01 (0.98–1.03)

 miR-150

154

1.04 (1.00–1.08)

 miR-16-2

153

1.02 (0.98–1.07)

 miR-17

129

1.01 (0.97–1.05)

 D/ND miR-17

154

0.56 (0.24–1.30)

 miR-191

151

1.52 (1.12–2.05)

 D/ND miR-200b

154

1.21 (0.40–3.64)

 miR-20a

116

1.03 (0.95–1.12)

 D/ND miR-20a

154

1.58 (0.61–4.13)

 miR-223

154

1.24 (0.999–1.54)

 miR-23a

154

1.20 (1.04–1.40)

 miR-24

154

1.20 (1.08–1.35)

 miR-25

154

1.04 (0.99–1.10)

 miR-26a

154

0.79 (0.63–0.99)

 miR-27a

154

1.08 (0.88–1.33)

 miR-29b

154

1.03 (0.98–1.08)

 miR-30a

154

1.02 (0.99–1.06)

 miR-330

54

1.08 (0.995–1.17)

 D/ND miR-330

154

0.48 (0.19–1.19)

 miR-451

154

1.04 (0.98–1.11)

 miR-503

117

0.99 (0.94–1.04)

 D/ND miR-503

154

0.99 (0.43–2.27)

 D/ND miR-663

154

0.53 (0.06–4.10)

microRNA

MELD aSHR (95% CI)

 

(B)

 miR-150

1.03 (0.98–1.08)

 

 miR-191

1.85 (1.32–2.60)

 

 miR-23a

1.08 (0.87–1.33)

 

 miR-24

1.10 (0.93–1.30)

 

 miR-26a

0.84 (0.66–1.07)

 

microRNA

CP aHR (95% CI)

 

(C)

 miR-150

1.02 (0.98–1.07)

 

 miR-191

1.63 (1.19–2.24)

 

 miR-23a

1.08 (0.92–1.28)

 

 miR-24

1.06 (0.92–1.21)

 

 miR-26a

0.83 (0.66–1.05)

 

microRNA

MELD aSHR (95% CI)

 

(D)

 miR-191 (ARLD)

1.88 (1.30–2.72)

 

 miR-191 (Ascites)

1.91 (1.37–2.65)

 

 miR-16-2 (dCLD)

1.08 (1.01–1.15)

 

 miR-24 (dCLD)

1.40 (1.04–1.90)

 

microRNA

CP aSHR (95% CI)

 

(E)

 miR-191 (ARLD)

1.66 (1.13–2.43)

 

 miR-191 (Ascites)

1.59 (1.16–2.19)

 

 miR-24 (dCLD)

1.36 (1.01–1.82)

 
  1. (A) Competing risk analysis for 1 year risk of mortality. (B) MELD adjustment of prevalently expressed microRNA which discriminated 1 year risk of mortality. Performance of MELD adjusted miR-191; n = 148, Wald Chi2 = 26.31, p < 0.001*. (C) CP adjustment of prevalently expressed microRNA which discriminated 1 year risk of mortality. Performance of CP adjusted miR-191; n = 148, Wald Chi2 = 53.69, p < 0.001*. (D) microRNA which discriminated outcome on sensitivity analyses and remained significant following adjustment for MELD. (E) microRNA which discriminated outcome on sensitivity analyses and remained significant following adjustment for CP. D/ND = microRNA converted into categorical variable and marked as detected = 1 or not detected = 0. See Supplementary Tables 8–10 for model performance.
Back to article page